Illumina Announces Initial Customer Orders for the Global Screening Array

SAN DIEGO–(BUSINESS WIRE)–Illumina,
Inc. (NASDAQ: ILMN) today announced that it has signed deals with 12
customers for its new Infinium®
Global Screening Array (GSA). In total, the company has received
orders for more than 3 million samples of the new consortia-developed
array. Initial customers include human disease researchers at The Broad
Institute and deCODE Genetics, health systems Avera Health, Codigo46,
Diagnomics, Eone Diagnomics Genome Center (EDGC), Sanford Health and
UCLA Health System, genomic service providers Centre National de
Genotypage, Human Genomics Facility HuGeF, Erasmus MC, Life and Brain,
and consumer genomics company 23andMe, Inc.
“The array content includes highly predictive hand-curated content, as
well as high value markers for translational research applications and
sample quality control (QC) designed to be useful across a broad range
of applications, populations and diseases,” said Benjamin Neale, PhD,
Assistant Professor, Analytic and Translational Genetics Unit,
Massachusetts General Hospital and The Broad Institute, who led the
predictive content selection for the consortia.
“We were impressed that the GSA included content applicable to a range
of clinical research activities across our healthcare ecosystem. For the
moment, this is an exceptional research opportunity,” said Dan
Geschwind, MD, PhD, Gordon and Virginia MacDonald Distinguished
Professor in Neurology, Psychiatry and Human Genetics and Senior
Associate Dean and Associate Vice Chancellor for Precision Medicine, at
UCLA. “As genetics and genomics becomes incorporated into clinical
practice in the future, we expect to be able to use these data to make
the care that we deliver in UCLA health more personalized.”
The GSA is a highly economical tool for genetic risk screening of large
global populations. With volume discounts enabling price points below
$40 per sample, it offers unparalleled genomic coverage and imputation
performance across 26 continental populations and features approximately
50,000 hand-curated variants relevant to clinical research, including
markers for pharmacogenomics, newborn screening research, risk profiling
and confirmation of putative clinical associations. Leveraging the
24-sample Infinium format, the array includes 660,000 markers, and
allows for the cost-effective addition of up to 50,000 custom markers.
“The early adoption of the GSA, represented by these deals, illustrates
the widespread market demand for genotyping products and the continued
relevance of arrays in human disease and translational research,” said
Rob Brainin, Vice President and General Manager, Applied Genomics at
Illumina. “We expect that the value of the content on this array will
lead to widespread use in clinical research, including precision
medicine programs, predictive risk screening, large scale genome-wide
association studies, and in biobank sample characterization and quality
control.”
The GSA will begin shipping in the second half of 2016. Orders received
to date occurred in the first half of 2016. For more information, visit www.illumina.com/GlobalScreeningArray.
About Illumina, Inc.
Illumina is improving human health by unlocking the power of the genome.
Our focus on innovation has established us as the global leader in DNA
sequencing and array-based technologies, serving customers in the
research, clinical and applied markets. Our products are used for
applications in the life sciences, oncology, reproductive health,
agriculture and other emerging segments. To learn more, visit www.illumina.com
and follow @illumina.
Forward-Looking Statements
This release may contain forward-looking statements that involve risks
and uncertainties. Important factors that could cause actual results to
differ materially from those in any forward-looking statements are
detailed in our filings with the Securities and Exchange Commission,
including our most recent filings on Forms 10-K and 10-Q, or in
information disclosed in public conference calls, the date and time of
which are released beforehand. We do not intend to update any
forward-looking statements after the date of this release.